JON R. SHERMAN, M.D., F.A.C.P., F.A.C.C., F.S.C.A.I.

The Paul Merage School of Business

University of California, Irvine

Sequoia Hospital

170 Alameda De Las Pulgas

Redwood City, CA 94062

Baylor University Medical Center

3500 Gaston Avenue

Dallas, TX 75248

University of Colorado Health Sciences Center

4200 East Ninth Avenue

Denver, CO 80262

University of Texas Health Science Center

7000 Fannin, Suite 2250

Houston, TX 77030

Plan II Liberal Arts Honors Program

University of Texas at Austin, Main Bldg., Room 1

Austin, TX 78712

Internal Medicine, Cardiovascular Diseases and Interventional Cardiology

ACLS/BLS, recertified 2016

Diplomate ABIM, Subspecialty Board of Interventional Cardiology, recertified 2011

Diplomate ABIM, Subspecialty Board of Cardiovascular Diseases, recertified 2009

Diplomate ABIM, American Board of Internal Medicine

Level II Certification, Society of Cardiovascular Computed Tomography

Federation of State Medical Boards

Medical Center of the Rockies, 2500 Rocky Mountain Avenue, Loveland, CO 80538 04/17-present

St. Jude Medical Center, 101 East Valencia Mesa Drive, Fullerton, California 92835 04/98-03/17

Placentia-Linda Hospital, 1301 Rose Drive, Placentia, California 92870 11/09-03/17

UCI Medical Center, 101 The City Drive South, Orange, CA 92868-3298 02/04-01/17

Valley View Hospital, 1906 Blake Avenue, Glenwood Springs, CO 81601 06/14-12115 (Locurns)

Longmont United Hospital, 1950 Mountain View Avenue, Denver, CO 80501 10/15-12116 (Locums)

Denver Health, 777 Bannock St., Denver, CO 80204 06/16-12/16 (Locurns)

Harbor Heart 07/07-04117

St. Jude Heritage Medical Group 04/98-07/07

Phoenix Heart 12/97-04/98

HeartPlace 09/96-12/97

Assistant Clinical Professor, Cardiology, 2004-2017

Relevance Reviewer, American Board of Internal Medicine

Interventional Cardiology Board Exam 2005-2015

Heart Failure Society of America (HFS), Member 2003

Society for Cardiovascular Angiography and Interventions (SCAI), Fellow 2002

American College of Chest Physicians (ACCP), Fellow 2002

American College of Cardiology (ACC), Fellow 2000

American College ofPhysicians (ACP), Fellow 1999

Nuclear Cardiology

Transthoracic, Transesophageal and 3-D Echocardiography, CIMT

Stress Echocardiography and Exercise Treadmill Testing

Congestive Heart Failure

Cardiac Rhythm Management: Pacemaker/ICD/ILR Implantation and Follow-up

Electronic Health Records, Medical Informatics

Harbor Heart, Founder and President 2007-2017

St. Jude Medical Center, Medical Director, Intensive (Omish) Cardiac Rehab 2015-2017

St. Jude Medical Center, Medical Director, Outpatient Cardiac Rehabilitation 2013-2017

St. Jude Medical Center Cardiothoracic Department, Chairman 2006, 2007

520 Broadway, Suite 200, Santa Monica, CA 90401

Gastroenterology, 95:394-401, 1988.

2. Sherman, J.R. and Anwar, A. et al. Distal Vessel Pullback Angiography and Pressure GradientMeasurement: An Innovative Diagnostic Approach to the

No-reow

Phenomenon. Catheterizationand Cardiovascular Diagnosis, 39:1-6, 1996.

3. Del Campo, C, and Sherman, J. Tricuspid Valve Replacement: Results Comparing Mechanicaland Biological Prostheses. Ann Thoracic Surg 69:1295,

2000.

4. Tovar, Eduardo A., Sherman, Jon R., et al. Aortoscopy: A Less Invasive Intraoperative Method toAssess the Aortic Valve. Ann Thoracic Surg 73:284-286,

2002.

5. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., Peter Rakovec, M.D. J. BenezetPenaranda, M.D., Jon R. Sherman, M.D., Todd J. Shelton,

M.S., Cathy Zeng, M.S., and PaulWang, M.D. for the CAPTURE Trial Investigators. Factors Inuencing

Pacemaker GeneratorLongevity: Results from the

Complete Automatic Pacing Threshold Utilization Recorded in theCAPTURE Trial. PACE 33:1020-1030, 2010.

1. Sherman, J.R., and Weinberg, R.B. Serum Apolipoprotein A-IV and Lipoprotein Cholesterol inPatients Undergoing Total Parenteral Nutrition.

Gastroenterology, 92; 5(2): 1805, May 1987.

2. Hener,

K.D., and Sherman, J.R. et at. Predicting Peak Exercise Heart Rate From Age In CardiacPatients: Inuence

of Medications and Gender.

Medicine and Science in Sports and Exercise, 26Suppl; 5. S184, May 1994.

3. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., J. Benezet Penaranda, M.D.,Jon R. Sherman, M.D., Raymond Gendreau, M.D., Yves R.

Vandekerckhove, M.D.,Peter Rakovec, M.D., Jon Seltzer, M.S., Benjamin Rhodes, M.S., Michael Hull, M.S. Eect

of Post-Mode Switch Overdrive Pacing on

Atrial Tachyarrhythmia Average Daily Burden in LargeRandomized Trial. Heart Rhythm Society, May 2009.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-findingStudy of Lercanidipine Hydrochloride in Patients with Essential Hypertension.

An Open-label Evaluation of the effectiveness of Micardis (Telmisartan) on Blood Pressure Controland Quality of Life in Patients with Essential Hypertension.

A phase IIIb, randomized, open-label trial with 3 parallel groups: full dose TNK-tPA together with heparin sodium; full dose TNK-tPA together with Enoxaparin; half doseTNK-tPA together with Abciximab and heparin sodium in patients with acute myocardial infarction.

A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCL vs.Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA 1).

A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous Dosing Regimens of h5Gl.l-scFv in Patients with Acute Myocardial Infarction Undergoing Thrombolytic Reperfusion Therapy.

A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous DosingRegimens ofh5G l.l-scFv in Patients with Acute Myocardial Infarction UndergoingPercutaneous Transluminal Coronary Angioplasty Reperfusion Therapy.

An Open-Label, Long-Term, Safety Study ofRanolazine SR for Chronic Stable AnginaPectoris at Doses of 500 mg, 750 mg and 1000 mg Twice a Day Administered inCombination with Background Anti-Anginal Therapy (CVT-3034).

A Double-Blind, Randomized, Stratified, Placebo-Controlled, Parallel Study of Ranolazine SR at Doses of 750 mg Twice a Day and 1000 mg Twice a Day in Combination with Other Anti-Anginal Medications in Patients with Chronic Stable Angina Pectoris.

A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of WeeklyAzithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposureto C. Pneumoniae.

A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the ClinicalEfficacy and Tolerability of Early Treatment with Simvastatin 40 mg Daily for 30 Days,Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary

Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin, and in Optimally-Treated STElevation Acute Coronary Syndrome Patients.

A Multi-center, Randomized, Double-Blind, Placebo-controlled Study of the Effects on Blood Pressure ofTreatment with Nebivolol or Hydrochlorothiazide Alone and in Combination in Subjects with Mild toModerate Systemic Hypertension.

A Multicenter, Double-Blind, Randomized, Parallel, 28-week Study to Evaluate the Efficacy and Safetyof Simvastatin 80mg/day versus Atorvastatin 80mg/day in patients with Hypercholesterolemia (CHESScomparative HDL Efficacy and Safety Study).

Omapatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE)A Multicenter, Randomized, Double-Blind, Placebo-controlled, dose-ranging study of the long term (12weeks) Hemodynamic Effects, Safety, and Tolerability of study medication, a selective Endothelin-AReceptor Antagonist, in the Treatment of Heart Failure.

Study of the Costs Associated with the Use of the ACS Multi-link TristarrM Coronary Stent SystemCompared to Costs Associated with the Use of Other Stent Systems.

Effects of Oral N0-1886 on Lipoproteins in Subjects with Type II Diabetes Mellitus Who areReceiving Statin Therapy.

A Multicenter, randomized, controlled study in which patients are assigned in 1:1Proportions to use ofTRAPTM VFS device or control group without use of system.Determine the effectiveness of the TRAP VFS in providing distal embolizationProtection in coronary SVG intervention with PTCA and/or stenting.

Silent Atrial Fibrillation Detection with Stored EGMs (SAFE) Study. A Guidant U.S. MulticenterClinical Field Following Study. "Incidence of Asymptomatic Atrial Fibrillation in Bradycardia Patientswith Sick Sinus Syndrome."

A Phase III Randomized, Parallel, Double-Blind, Multicenter, Placebo-controlled Study of the Effect ofPexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary ArteryBypass Graft (CABG) Surgery with Cardiopulmonary Bypass.

Synergistic Effects of Risk Factors of Sudden Cardiac Death (SERF) Study. A Guidant MulticenterClinical Application Research Field Following Study.

Value of Electronically Recorded and Interrogated Follow-up via lPG Exported Data (VERIFIED). AMedtronic Pacemaker Registry.

Reported Atrial Fibrillation and Inappropriate Mode Switch in Sick Sinus Syndrome Patients (RARE)study. St. Jude Medical.

Clinical Observations on Usage, Learning and Trends (CONSULT) Kappa Pacemaker Program.Medtronic.

Limiting Chronotropic Incompetence for Pacemaker Recipients (LIFE) Study. Guidant.Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias (AWARE). St. JudeMedical.

Complete Automatic Pacing Threshold Utilization Recorded by EnPulse (CAPTURE) Clinical Study:A One-to-one Randomized, Multicenter, Prospective Study in Which Patients Receiving New EnPulsePacemaker Implants will be Randomized to Routine Manual Follow-up and Follow-up Using theAutomatic Features. Medtronic.

Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy andSafety of Two Blinded Doses of Dabigatran Etixilate with Open Label Warfarin for the Prevention ofStroke and Systemic Embolism in Patients with Non-Valvular AtrialFibrillation: Prospective, Multi-Centre, Parallel-Group Non-Inferiority Trial (RE-LY Study).Boehringer lngelheim Pharmaceuticals, Inc.

TREXIMET -Phase IIIb study to evaluate the efficacy and safety of a range of doses of a combinationproduct containing Sumatriptan and Naproxen Sodium for the acute treatment of migraine in adolescentmigrainers ages 12 through 17. GSK Adolescent Migraine Study.

A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Renal Impairment.

A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Asthma or Chronic Obstructive Pulmonary Disease(COPD).